Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Large clinical trials running for several years show that GLP-1s not only improve sugar and weight but also reduce heart and kidney risks in many people with type 2 diabetes, with an acceptable safety profile when monitored
Impact on outcomes across KDIGO-2012 AKI criteria according to baseline renal function
Comparative transcriptome analysis reveals that Exendin-4 improves steatosis in HepG2 cells by modulating signaling pathways related to lipid metabolism
345,346 GLP-1 may also reduce the expression of cartilage-degrading enzymes by inhibiting the MAPK pathway or activating anti-inflammatory pathways such as PI3K/Akt, thereby alleviating cartilage damage
FIGURE 1 Notably, the insulinotropic actions of circulating GLP-1 are facilitated through a two-domain binding interaction with GLP-1R (Figure 2), a structurally well-characterized prototypical class B GPCR, which recruits the G s -subunit of the heterotrimeric G-protein for cAMP-mediated downstream signaling, involving protein kinase A (PKA) and exchange protein activated by cAMP (EPAC), leading to insulin exocytosis
Laboratory use only.
US$ 29.17
US$ 29.40
US$ 23.92
US$ 25.01
